Drug Trial Radar · NCT06664502
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Nov 12, 2024
Primary completion
Mar 25, 2026
Study completion Aug 11, 2026
Sponsor
- Lead sponsor
- EyeBiotech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part, 2 doses of EYE201 will be selected and their effectiveness will be compared. This portion of the study assesses the safety and preliminary efficacy of EYE201 in patients with diabetic macular edema (DME) or neovascular macular degeneration (NVAMD). Approximately 80 participants will be entered in this part of the study.
Conditions
- Diabetic Macular Edema (DME)
- Neovascular Age-related Macular Degeneration (NVAMD)
- BRVO - Branch Retinal Vein Occlusion
Interventions
EYE201Drug
EYE201 solution for intravitreal administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 12 Weeks
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Scottsdale, Arizona
Scottsdale, Arizona
Modesto, CA
Modesto, California
Mountain View, California
Mountain View, California
Sacramento, CA
Sacramento, California
Sacramento, California
Sacramento, California
Deerfield Beach, FL
Deerfield Beach, Florida
Lemont, IL
Lemont, Illinois
Hagerstown, Maryland
Hagerstown, Maryland
Madison, Mississippi
Madison, Mississippi
Bloomfield, New Jersey
Bloomfield, New Jersey
Asheville, NC
Asheville, North Carolina
Wake Forest, NC
Wake Forest, North Carolina
West Columbia, South Carolina
West Columbia, South Carolina
Germantown, Tennessee
Germantown, Tennessee
Knoxville, TN
Knoxville, Tennessee
Nashville, Tennessee
Nashville, Tennessee
Abilene, Texas
Abilene, Texas
Amarillo, Texas
Amarillo, Texas
Austin, Texas
Austin, Texas
Bellaire, Texas
Bellaire, Texas
Bellaire, TX
Bellaire, Texas
Dallas, Texas
Dallas, Texas
Plano, TX
Plano, Texas
Round Rock, TX
Round Rock, Texas
San Antonio, Texas
San Antonio, Texas
Woodlands, Texas
The Woodlands, Texas
Arecibo, PR
Arecibo, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.